- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Do | Fitbit enlists Pfizer, Bristol-Myers Squibb to bring arrhythmia detection to its fitness trackers | ||
| Do | Blocking tumor evolution to halt cancer drug resistance | ||
| Do | Protein-degrading Plexium debuts with $28M to attack cancer, neurodegenerative disease | ||
| Do | EuroBiotech Report-Healx and Abalos raise cash, Ipsen bags Blueprint drug, Gilead and ReNeuron | ||
| Do | Syros cans solid tumor drug after seeing early clinical data | ||
| Do | AstraZeneca gets Q2 2020 PDUFA date for breast cancer ADC | ||
| Do | NSF International buys up CRO Amarex | ||
| Do | European VC Sofinnova raises €333M for early-stage biotech, medtech firms | ||
| Do | ArsenalBio joins next-gen cell therapy field with $85M A round | ||
| Do | Closed-loop artificial pancreas from Tandem, Dexcom aces type 1 diabetes study | ||
| Mi | Novartis' Sandoz drops out of prescription app deal with Pear Therapeutics | ||
| Mi | MedImmune's top cancer researcher jumps ship to small biotech | ||
| Mi | Alexion inks deal to acquire Achillion for $930M upfront | ||
| Mi | Ipsen bags Blueprint drug to move deeper into ultra-rare disease | ||
| Mi | Lilly's Armo buyout drug a bust in pancreatic cancer | ||
| Mi | Roche dumps early pipeline efforts as sales jump | ||
| Mi | Healx raises $56M to launch 40 rare disease R&D programs | ||
| Di | Philips to bring Spencer Health's digital pill hub to Europe | ||
| Di | Abbott partners with Omada, Tandem to extend the reach of its FreeStyle Libre CGM | ||
| Di | Eli Lilly to shutter neuroscience R&D center next year | ||
| Di | Woodford cut down as fund chopped and burned | ||
| Di | Boehringer's VC wing backs anti-cancer virus startup | ||
| Di | Reata shocks analysts with pivotal win in Friedreich's ataxia | ||
| Di | Aeglea, long-term Eli Lilly veteran nabs CMO job at Checkmate | ||
| Mo | Marrying CRISPR with immuno-oncology to defeat remote tumors |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
